Company profile
SpyGlass Pharma, Inc.
NASDAQ:SGPMedical/Dental Instruments
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06120842 | phase1_2 | active_not_recruiting | 2023-10-13 | 2025-01-31 | SpyGlass Pharma, Inc. | Evaluation of the Bimatoprost Implant System Used in Combination With the SpyGlass Intraocular Lens Compared to Timolol Ophthalmic Solution |
| NCT07218783 | phase3 | recruiting | 2025-10-15 | 2029-03-31 | SpyGlass Pharma, Inc. | Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhine) |
| NCT07218796 | phase3 | recruiting | 2025-10-28 | 2029-05-31 | SpyGlass Pharma, Inc. | Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhone) |
| NCT07641296 | phase1 | not_yet_recruiting | 2026-07-31 | 2027-02-28 | SpyGlass Pharma, Inc. | Evaluation of the Safety, Efficacy, Dose Response of the Bimatoprost Drug Ring System (BIM-DRS) in Pseudophakic Patients Diagnosed With Open Angle Glaucoma or Ocular Hypertension |
FDA applications (0)
No records yet.